About Mesoderm posterior protein 2
Mesoderm posterior protein 2 (MESP2) is a protein
from Homo sapiens identified by UniProt accession
Q0VG99, 397 residues long.
MolForge cross-references it against 0 known binders and
94 disease associations.
Target properties
| Protein name | Mesoderm posterior protein 2 |
| UniProt accession | Q0VG99 |
| Gene | MESP2 |
| Organism | Homo sapiens |
| Length | 397 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (94)
Diseases linked to this target (Open Targets).
- autosomal recessive spondylocostal dysostosis · score 0.70
- neurodegenerative disease · score 0.30
- electrocardiography · score 0.23
- reticulocyte count · score 0.21
- genetic disorder · score 0.19
- spondylocostal dysostosis · score 0.13
- cervical rib syndrome · score 0.10
- Scheuermann disease · score 0.09
- posterior fusion of lumbosacral vertebrae-blepharoptosis syndrome · score 0.08
- intraocular pressure measurement · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q0VG99-F1 | alphafold | PREDICTED | 54.17 | — |
Amino-acid sequence (397 residues)
MAQSPPPQSL LGHDHWIFAQ GWGWAGHWDS TSPASSSDSS GSCPCDGARG LPQPQPPSCS SRAAEAAATT PRRARTGPAG GQRQSASERE KLRMRTLARA LHELRRFLPP SLAPAGQSLT KIETLRLAIR YIGHLSAVLG LSEESLQCRR RQRGDAGSPW GCPLCPDRGP AEAQTQAEGQ GQGQGQGQGQ GQGQGQGQGQ GQGQGRRPGL VSAVLAEASW GSPSACPGAQ AAPERLGRGV HDTDPWATPP YCPKIQSPPY SSQGTTSDAS LWTPPQGCPW TQSSPEPRNP PVPWTAAPAT LELAAVYQGL SVSPEPCLSL GAPSLLPHPS CQRLQPQTPG RCWSHSAEVV PNSEDQGPGA AFQLSEASPP QSSGLRFSGC PELWQEDLEG ARLGIFY
Explore Mesoderm posterior protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets